Explain two possible ways a drug could be designed to inhibit the activated HER2 signal transduction pathway downstream of the receptors to inhibit breast cancer.
Therapies in development focus on telomerase inhibition. What is a possible concern if a telomerase inhibitor is administered systemically to a cancer patient?
October 24, 2018Propose alternative treatments that may be more successful against tumors and that do not involve the apoptotic pathway (caspase-independent pathways).
October 24, 2018Explain two possible ways a drug could be designed to inhibit the activated HER2 signal transduction pathway downstream of the receptors to inhibit breast cancer.
Explain two possible ways a drug could be designed to inhibit the activated HER2 signal transduction pathway downstream of the receptors to inhibit breast cancer.
Some patients with breast cancer express HER2 (an RTK in the epidermal growth factor receptor famil Show more Some patients with breast cancer express HER2 (an RTK in the epidermal growth factor receptor family member) at levels much higher than normal and the receptor is activated even in the absence of ligand. It is thought that the high expression of HER2 contributes to breast cancer progression and these HER2 positive patients have a much worse prognosis and are more likely to die from the disease. Active research is being done to develop drug inhibitors of HER2. A. Explain two possible ways a drug could be designed to inhibit the activated HER2 receptors to inhibit breast cancer. B. Explain two possible ways a drug could be designed to inhibit the activated HER2 signal transduction pathway downstream of the receptors to inhibit breast cancer.